drugset / Trial / NCT04012879
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1
Unknown
12 enrolled
Chinese PLA General Hospital
Shenzhen University General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory acute lymphoblasic leukemia.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2021-04-30
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | 50000 cells/kg | Other |